Literature DB >> 26885860

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.

Omkar U Kawalekar1, Roddy S O'Connor2, Joseph A Fraietta1, Lili Guo3, Shannon E McGettigan1, Avery D Posey1, Prachi R Patel1, Sonia Guedan1, John Scholler1, Brian Keith1, Nathaniel W Snyder, Nathaniel Snyder4, Ian A Blair, Ian Blair3, Michael C Milone5, Carl H June6.   

Abstract

Chimeric antigen receptors (CARs) redirect T cell cytotoxicity against cancer cells, providing a promising approach to cancer immunotherapy. Despite extensive clinical use, the attributes of CAR co-stimulatory domains that impact persistence and resistance to exhaustion of CAR-T cells remain largely undefined. Here, we report the influence of signaling domains of coreceptors CD28 and 4-1BB on the metabolic characteristics of human CAR T cells. Inclusion of 4-1BB in the CAR architecture promoted the outgrowth of CD8(+) central memory T cells that had significantly enhanced respiratory capacity, increased fatty acid oxidation and enhanced mitochondrial biogenesis. In contrast, CAR T cells with CD28 domains yielded effector memory cells with a genetic signature consistent with enhanced glycolysis. These results provide, at least in part, a mechanistic insight into the differential persistence of CAR-T cells expressing 4-1BB or CD28 signaling domains in clinical trials and inform the design of future CAR T cell therapies.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26885860     DOI: 10.1016/j.immuni.2016.01.021

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  339 in total

Review 1.  Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.

Authors:  Premal D Lulla; Maksim Mamonkin; Malcolm K Brenner
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360

Review 2.  Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.

Authors:  Shivani Srivastava; Stanley R Riddell
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

3.  Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.

Authors:  Christopher A Pennell; Jessie L Barnum; Cameron S McDonald-Hyman; Angela Panoskaltsis-Mortari; Megan J Riddle; Zhengming Xiong; Michael Loschi; Govindarajan Thangavelu; Heather M Campbell; Meghan D Storlie; Yosef Refaeli; Scott N Furlan; Michael C Jensen; Leslie S Kean; Jeffrey S Miller; Jakub Tolar; Mark J Osborn; Bruce R Blazar
Journal:  Mol Ther       Date:  2018-04-07       Impact factor: 11.454

4.  Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.

Authors:  Rebecca A Gardner; Olivia Finney; Colleen Annesley; Hannah Brakke; Corinne Summers; Kasey Leger; Marie Bleakley; Christopher Brown; Stephanie Mgebroff; Karen S Kelly-Spratt; Virginia Hoglund; Catherine Lindgren; Assaf P Oron; Daniel Li; Stanley R Riddell; Julie R Park; Michael C Jensen
Journal:  Blood       Date:  2017-04-13       Impact factor: 22.113

5.  Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma.

Authors:  Peter J Siska; Kathryn E Beckermann; Frank M Mason; Gabriela Andrejeva; Allison R Greenplate; Adam B Sendor; Yun-Chen J Chiang; Armando L Corona; Lelisa F Gemta; Benjamin G Vincent; Richard C Wang; Bumki Kim; Jiyong Hong; Chiu-Lan Chen; Timothy N Bullock; Jonathan M Irish; W Kimryn Rathmell; Jeffrey C Rathmell
Journal:  JCI Insight       Date:  2017-06-15

6.  A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

Authors:  Donald M O'Rourke; MacLean P Nasrallah; Arati Desai; Jan J Melenhorst; Keith Mansfield; Jennifer J D Morrissette; Maria Martinez-Lage; Steven Brem; Eileen Maloney; Angela Shen; Randi Isaacs; Suyash Mohan; Gabriela Plesa; Simon F Lacey; Jean-Marc Navenot; Zhaohui Zheng; Bruce L Levine; Hideho Okada; Carl H June; Jennifer L Brogdon; Marcela V Maus
Journal:  Sci Transl Med       Date:  2017-07-19       Impact factor: 17.956

7.  Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability.

Authors:  Sonia Guedan; Aviv Madar; Victoria Casado-Medrano; Carolyn Shaw; Anna Wing; Fang Liu; Regina M Young; Carl H June; Avery D Posey
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

8.  CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

Authors:  Julia Bluhm; Elisa Kieback; Stephen F Marino; Felix Oden; Jörg Westermann; Markus Chmielewski; Hinrich Abken; Wolfgang Uckert; Uta E Höpken; Armin Rehm
Journal:  Mol Ther       Date:  2018-06-18       Impact factor: 11.454

Review 9.  Immunometabolism of regulatory T cells.

Authors:  Ryan Newton; Bhavana Priyadharshini; Laurence A Turka
Journal:  Nat Immunol       Date:  2016-05-19       Impact factor: 25.606

Review 10.  The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

Authors:  Lindsay K Ward-Kavanagh; Wai Wai Lin; John R Šedý; Carl F Ware
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.